At a glance
ClinicalIndex Comparison RecordN/ACompleted· 996 enrolled
Drug / intervention
Observationalother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN® (Latanoprost) as First-Line Monotherapy and as Second-Line Monotherapy After Beta-Blockers Therapy Failure
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Jun 14, 2007·Updated Mar 1, 2021
In Brief
An observational study evaluating Observational for Glaucoma,Open-Angle and Ocular Hypertension. Completed, enrolled 996 participants.
Detailed Summary
The primary objective is to evaluate the Intraocular pressure reducing effect of Xalatan over 3 months. The secondary objective is to study the other efficacy parameters during treatment for 3 months
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma,Open-Angle, Ocular Hypertension
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJun 2007
Primary CompletionJan 2008
TodayJul 2026
First PostedJun 14, 2007
Enrollment StartJun 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 19.1 years ago
Interventions
Observationalother
This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.